Lamivudine News and Research

RSS
Study explores links between antiretroviral prophylaxis, cleft lip and palate

Study explores links between antiretroviral prophylaxis, cleft lip and palate

WHO approves three Mylan ARV therapies to treat HIV/AIDS

WHO approves three Mylan ARV therapies to treat HIV/AIDS

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Study shows possibility of women living with AIDS to breastfeed with lower risk

Study shows possibility of women living with AIDS to breastfeed with lower risk

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA